News

Treatment with Kynmobi (apomorphine hydrochloride), an approved under-the-tongue therapy for “off” episodes in Parkinson’s disease, does not substantially alter heartbeat dynamics at approved doses, according to new clinical trial data. The study, “A Randomized Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson’s…

Researchers have developed a new method of temporarily opening the selective blood-brain barrier (BBB) to allow therapeutic molecules greater access to the brain. Difficulties in developing molecules that can cross this barrier have long hindered the development of treatments for neurological diseases, like Parkinson’s disease. The technique could now…

Buntanetap, Annovis Bio’s investigational oral treatment for neurodegenerative diseases, was safe and showed effectiveness in people with early-stage Parkinson’s disease, a presentation of Phase 2 trial data showed, paving the way for Phase 3 testing in a larger patient group. The U.S. Food and Drug Administration recently gave the…

The Parkinson’s Foundation invested $1.1 million in two fellowships programs aimed at giving neurologists and nurse practitioners more specialized and expert training in Parkinson’s disease (PD). Specifically, the investment supports the Institutional Movement Disorder (IMDS) Fellowship Program for neurologists and the newly opened Nurse Practitioner (NP) Fellowship in Movement Disorders.

A new project by scientists at the University of Michigan (UM) aims to design a prototype autonomous vehicle that’s specifically designed to help meet the needs of people living with Parkinson’s disease. The project, called “Inclusive Design in Shared Autonomous Vehicles for People with Parkinson’s Disease,” is being funded…

A Parkinson’s-associated variant in the LRRK2 gene affects the gene’s activity in a single group of brain cells: microglia, the resident immune cells of the brain. “Our study demonstrates that cell type should be considered when evaluating the role of noncoding variation in disease pathogenesis [development],” the researchers wrote. The…

A more extensive biopsy involving larger tissue samples taken from the gastrointestinal (GI) tract of people with Parkinson’s disease improves the ability to identify alpha-synuclein protein clumping, researchers in a small study reported. These findings support more extensive GI biopsies as a diagnostic tool for Parkinson’s and other…

ZyVersa Therapeutics announced that a grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) will support work into IC 100 as a potential antibody-based therapy for Parkinson’s disease. Robert Keane, PhD, and Juan Pablo de Rivero Vaccari, PhD, professors at the University of…

Multiple alterations to a class of fat (lipid) molecules called glycosphingolipids (GSLs) are observed in the blood of people with Parkinson’s disease compared with those without the disease, according to a recent study. These changes, some of which are linked to Parkinson’s symptoms such as motor and cognitive…

Among people with Parkinson’s disease, those with the skin disease psoriasis tend to experience slightly faster disease progression, according to a new analysis of genetic data. “These findings provided a better understanding of the role of psoriasis in the pathogenesis [disease development] of [Parkinson’s], and had clinical implications for…